Chordate Medical Holding AB (publ) (“Chordate”) announces today that the first seven patients have been included in the company’s post-Market Study PM010. The seven patients have been enrolled by the study at neurology clinics in Hull, Glasgow, Frankfurt, Essen, and Jerusalem.

“All participating clinics are led by reputable specialists, and it is satisfying that the first patients are now enrolled. The PM010 study is part of the regulatory requirement for the CE marking of migraine treatment but also holds significant importance in providing information to treating physicians about how often the treatment needs to be administered to different types of patients”, says Anders Weilandt, CEO of Chordate.

About PM010

The PM010 study is an ongoing, open post-marketing clinical follow-up investigation to follow long-term performance and safety of Chordate Medical’s preventive migraine treatment Ozilia® in subjects with chronic migraine during regular clinical treatment. The study will recruit 200 subjects and will be conducted at approximately 15 clinics in four European countries, the follow-up is 12 months. Data from this open study will be reported in intervals and used to fine-tune recommendations for the clinical treatment regime.

Chordate Medical’s CEO Anders Weilandt and CSO Jan Hermansson are currently in Barcelona at the European Headache Congress to present Ozilia to the gathered migraine and headache industry. The congress is attended by 2,200 delegates from both Europe and other markets, and the interest in Ozilia is continuing to grow.

“During the first days, we have generated an impressive number of leads from stakeholders who clearly indicate buying interest. Awareness of Ozilia is beginning to establish itself at very satisfactory levels. We cannot currently serve all interested stakeholders since some markets outside the EU and GCC require product registration – but the need for Ozilia as a drug-free treatment alternative for migraine is evident,” says Anders Weilandt.

Chordate is in Barcelona together with the company’s Italian distributor Vedise Hospital S.p.A, who will bring home a number of leads. EHC is one of the foremost meeting places for the headache and migraine sector, with representatives from both research and industry from around the world.

“In addition to significant interest from the healthcare sector, we also notice that the exploratory interest from the pharmaceutical industry has increased significantly compared to previous congresses where we have participated. It is evident that they both want to learn more and, at the same time, understand what we are doing.”

Biostock interviews Chordate Medical’s CSO Jan Hermansson about the inclusion of the first patient in the company’s open pilot study PM009. The purpose of the study is to evaluate the effectiveness of Chordate’s migraine treatment, Ozilia, in patients who do not respond to treatment with CGRP inhibitors and other treatment options.

“Of course, we hope that many patients will have a significant reduction in their migraine and days with headache. Every patient who reports improvement will be considered a success, especially since other alternatives have not had the desired effect […] The number of migraine and headache days is measured daily via an electronic diary. Even a reduction of 2 – 3 migraine days per month is considered a significant improvement for the patient. Since the study is open, we can continuously follow the patients and see the trends”, says Jan Hermansson to Biostock.

Read the full interview

Chordate Medical’s CEO, Anders Weilandt, and CSO, Jan Hermansson, will participate and exhibit at the European Headache Congress from December 6 to 9 alongside Chordate’s Italian distributor, Vedise Hospital S.p.A. Chordate will present Ozilia and share the case study from the migraine study PM007.

“EHC is one of the largest gatherings for physicians and professionals in the headache field in general, and the migraine sector in particular. We anticipate a significant number of Italian delegates at the congress, and Vedise can address inquiries about Ozilia,” says Anders Weilandt.

The theme of the 2023 European Headache Congress is “Headache: Expanding the horizon,” and over the four days of the congress, the latest developments and innovations in the headache field will be highlighted. In addition to Italy, delegates from other important European markets for Chordate.

“This is another opportunity for us to raise awareness about Ozilia. We have participated in several congresses in recent months, and the interest in Ozilia has been substantial,” says Anders Weilandt.

Chordate Medical Holding AB (publ) (“Chordate”) announced today that the first patient has been included in the company’s open pilot study PM009. The study aims to evaluate the effectiveness of Ozilia in the preventive treatment of patients with chronic migraine who do not respond to treatment with CGRP inhibitors and other migraine medications.

“PM009 is an important study with significant potential upside for the company. Every level of positive results from the study could represent a great opportunity for the company, as the patient group in question has very few treatment options left”, says Anders Weilandt, Chordate CEO.

PM009 is being conducted at King’s College in London with three to four referring clinics and Dr. Jan Hoffmann as the responsible principal investigator. The goal is to include 25–30 patients in the study.

“PM009 is a pilot study where we can learn more about how Ozilia can help people with chronic migraine who have no other options left. The patients participating in the study have already tried at least three other preventive medications before being treated with CGRP inhibitors, and when they also do not respond to CGRP, there are not many more possibilities. Hopefully, Ozilia can have a positive effect for some of them”, says Jan Hermansson, Chordate CSO.

Chordate Medical’s CEO, Anders Weilandt, recently returned from Saudi Arabia and the United Arab Emirates, where he met with both existing and potential clients, and signed an agreement with a new marketing agent for the UAE.

“It has been a rewarding week where, together with our General Manager for GCC, Alain Durante, and Janin Medical, we met several healthcare organizations interested in Ozilia. We also visited IMC International Medical Center Jeddah, which has been treating rhinitis with Ozilia for a long time, and Nadicare Clinics with now six sites around Jeddah, which recently started using Ozilia on the first clinic,” says Anders Weilandt.

The Gulf region has long been one of Chordate’s priority markets to demonstrate proof of concept, and Ozilia has been used by several private hospitals for the treatment of rhinitis for an extended period.

“It is clear that the demand for treatments like Ozilia is significant in the region, and after the gradual establishment of the rhinitis treatment in the market, the next step is to launch Ozilia for chronic migraine and simultaneously bring in more clients on the rhinitis side,” says Anders Weilandt.

In an interview with Biostock, CEO Anders Weilandt provides more details about Chordate Medical’s agreement to install Ozilia Migraine at a private specialist clinic in Germany for commercial use, and the company’s new market expert in the United Arab Emirates for the introduction of migraine and rhinitis treatment.

“It is very satisfying to achieve a breakthrough in Germany as it is one of the markets we are focusing on. This will undoubtedly make it easier to continue converting prospects into orders in Germany. our main focus is to build proof-of-concept (PoC) in the market, i.e. to show that we can gain customers and that they build up a volume of repeat patients. That is our strategic goal. In that process, revenues will also increase, which we are working towards, but the real goal is PoC.”

Read the full interview

Chordate Medical (“Chordate,” “the company”) has contracted MEDSWAN MEDICAL SUPPLIES L.L.C, Dubai, as a market expert in the United Arab Emirates (UAE) for the introduction of the company’s product Ozilia to the UAE market. As previously announced, the company intends to explore opportunities in the broader Gulf region based on the successes and experiences gained in Saudi Arabia, making the move into the UAE market a logical next step.

Medswan is owned and led by Hanna Hardwick, a Swedish Arabic-speaking businesswoman with 20 years of experience in leading sales and marketing positions within the medtech and pharma sectors in the MEA region. She has worked for global companies such as Sirtex, Terumo, Fresenius, Hilrom, and Siemens.

“Based on several important customer contacts for the UAE that we have collected at recent international congresses, we are expanding our focus primarily on chronic migraine in the Gulf region. Medswan will now register the products, a process estimated to take ten weeks, and concurrently launch and create market access for Ozilia. Hanna Hardwick has extensive experience in relevant specialist segments within medtech, a strong familiarity with market introductions, and a broad network,” says Anders Weilandt, CEO of Chordate.

“The healthcare market in the UAE is almost entirely private and relatively straightforward to access. In recent days, we have visited four leading neurologists at as many hospitals here in Dubai – there is no doubt that Ozilia is a drug-free alternative that doctors here see a significant need to have access to.”

For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Cell: +46 733-874277

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in Finland, Germany, the UK, Italy, Israel, and the Gulf region. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com

Chordate Medical has secured an agreement for the immediate installation of equipment and consumables for the Ozilia treatment for chronic migraines. The agreement was reached through the company’s marketing consultants in Germany. The customer is a private specialist clinic in Hamburg.

“It is very satisfying to achieve a breakthrough in Germany as it is one of the markets we are focusing on. This will undoubtedly make it easier to continue converting prospects into orders in Germany. The agreement came about thanks to the skilled work of our German market experts,” says Anders Weilandt, CEO of Chordate.

Chronic migraines in Germany
Migraine is one of the most common diseases globally, with approximately 12.5 million people in Germany suffering from migraines in some form. That’s about one in seven Germans. Globally, it affects around 1.2 billion people. Between 1.5 and 1.8 million Germans have chronic migraines. Migraine and headache care in the country are among the most advanced in Europe, and the market for migraine medications is one of the largest in the world. These conditions where part of the reason why Chordate conducted its recently concluded clinical study in Germany.

For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com
Cell: +46 733-874277

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine (formerly K.O.S), a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in Finland, Germany, the UK, Italy, Israel, and Saudi Arabia. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com The company’s Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB.

Ozilia has now been installed at the private healthcare company Nahdi Care Clinics’ hospital in Jeddah, Saudi Arabia. Chordate Medical received the order through the company’s distributor in Saudi Arabia, Janin Medical, in May 2023, and Nahdi Care Clinics is now offering Ozilia to its rhinitis patients.

“It’s a great feeling that the equipment is in place and operational, and Nahdi Care Clinics can now treat their patients with Ozilia. The installation also included training for the clinic staff. The next step is to take orders for Ozilia from one or more of Nahdi Care’s other three hospitals. It shouldn’t normally take this long between order and delivery; the delay is due to the fact that Janin Medical has undergone a fundamental restructuring, with the owning family taking over the company’s management – something we view positively, says Anders Weilandt, CEO of Chordate Medical”, says Anders Weilandt, CEO of Chordate Medical.

The prevalence of chronic rhinitis is high in Saudi Arabia due to air pollution in major cities, high incidence of mites and mold spores, combined with constant alternation between high outdoor temperatures and cold indoor environments.

“Alain Durante, the general manager of our representative office in Saudi Arabia, has, together with Janin Medical, done a great job in promoting Ozilia for rhinitis, in addition to the four installations we already have. The introduction of migraine is also being prepared while waiting for product registration to be completed”, says Anders Weilandt.